Women's Cancer Research Program The Women's Cancer Research Program (WCRP), led by Drs. Peggy Porter and Nicole Urban, brings together a highly cross-disciplinary group of investigators dedicated to reducing the incidence and subsequent mortality of breast and gynecologic cancers. The program fosters interdisciplinary research at the FHCRC, the UW, and in the clinical community to improve cancer prevention, detection, diagnosis, and treatment. It has 52 members from 2 institutions, 4 schools and 15 departments; 96% have peer-reviewed grant funding or are PI on a clinical trial. The program holds $11.2M in peer reviewed funding (direct dollars), of which $9.0M (80%) is from NCI. Program members have published 583 papers in the last 5 years, including 16% inter-institutional, 19% intra-programmatic, 35% inter-programmatic and 16% inter-institutional manuscripts. Central research themes of the program include improving strategies for identifying women at high risk for breast and gynecological cancer, developing and validating assays for early diagnosis of breast and gynecological cancer, improving the efficacy and safety of adoptive T-cell transfer for breast and gynecological cancer, and improving response and lowering resistance to various forms of chemotherapy for patients with breast and gynecological cancer. Recent scientific accomplishments include elucidation of the role in cervical cancer of viral load and variants in the persistence and progression of HPV infections; development of a small recombinant protein that has the potential to enhance the efficacy of monoclonal and chemotherapeutic agents in breast and ovarian cancer; comprehensive genetic testing to identify women with inherited mutations beyond those determined as BRCA1/2; use of HE4 in screening for epithelial ovarian cancer; role of contraceptive depo- medroxyprogesterone acetate, antihypertensives and lipid lowering medications in risk of breast cancer; improved strategies for adoptive T-cell therapy using central memory T-cells and chimeric antigen receptors; and quantitative FDG positron emission tomography (PET) to predict response to aromatase inhibitor in breast cancer. Many of the research, mentoring, project development and inter-and intra-programmatic interactions are centered on three large multidisciplinary grants: the Pacific Ovarian Cancer Research Consortium SPORE, Seattle Cancer Consortium Breast SPORE, and the NCI EDRN Clinical Validation Center. In addition, the program has a broad portfolio of outstanding interdisciplinary projects including those in imaging, immunotherapy and genetics. Program leadership continues to maintain an active agenda of seminars, pilot funding and biospecimen resources to promote programmatic aims and collaboration among Women's Cancer members and with members of other programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-43
Application #
9406726
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-01-01
Budget End
2018-12-31
Support Year
43
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Stromnes, Ingunn M; Hulbert, Ayaka; Pierce, Robert H et al. (2017) T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma. Cancer Immunol Res 5:978-991
Ladiges, Warren; Snyder, Jessica M; Wilkinson, Erby et al. (2017) A New Preclinical Paradigm for Testing Anti-Aging Therapeutics. J Gerontol A Biol Sci Med Sci 72:760-762
Hay, Kevin A; Hanafi, Laïla-Aïcha; Li, Daniel et al. (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 130:2295-2306
Miller, Natalie J; Church, Candice D; Dong, Lichun et al. (2017) Tumor-Infiltrating Merkel Cell Polyomavirus-Specific T Cells Are Diverse and Associated with Improved Patient Survival. Cancer Immunol Res 5:137-147
Turtle, Cameron J; Hay, Kevin A; Hanafi, Laïla-Aïcha et al. (2017) Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib. J Clin Oncol 35:3010-3020
Wang, Yu Winston; Reder, Nicholas P; Kang, Soyoung et al. (2017) Raman-Encoded Molecular Imaging with Topically Applied SERS Nanoparticles for Intraoperative Guidance of Lumpectomy. Cancer Res 77:4506-4516
Miles, Fayth L; Navarro, Sandi L; Schwarz, Yvonne et al. (2017) Plasma metabolite abundances are associated with urinary enterolactone excretion in healthy participants on controlled diets. Food Funct 8:3209-3218
Hanron, Amelia E; Billman, Zachary P; Seilie, Annette M et al. (2017) Multiplex, DNase-free one-step reverse transcription PCR for Plasmodium 18S rRNA and spliced gametocyte-specific mRNAs. Malar J 16:208
Ashenberg, Orr; Padmakumar, Jai; Doud, Michael B et al. (2017) Deep mutational scanning identifies sites in influenza nucleoprotein that affect viral inhibition by MxA. PLoS Pathog 13:e1006288
Paulson, Kelly G; Lewis, Christopher W; Redman, Mary W et al. (2017) Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer 123:1464-1474

Showing the most recent 10 out of 1144 publications